Cogentis Therapeutics is developing a drug to treat a family of neurodegenerative disorders, including Alzheimer's Disease, Pick's Disease, and our initial target condition, Frontotemporal Degeneration, also known as Frontotemporal Dementia (FTD).

Our drug can cross into the brain and prevent the process which leads to neural decay, dementia, and cell death. Due to advances in medical technology, we can target a previously inaccessible pathway and disrupt FTD before it begins.

2015 Boston Silver Winner